Registration
Welcome address A. Klinakis (GR)
Chair: V. Georgoulias (GR), Z.Lygerou (GR)
12.00-12.30 Precision Medicine and the ‘‘Genome of Greece” D. Thanos (GR)
12.30-13.00 Overview of HRD: From the bench to the clinic A. Klinakis (GR)
Light Lunch
Chairs: Th. Rampias (GR), S. Gagos (GR)
14.00-14.20 Mechanisms for DNA damage repair (DDR) D. Karagiannis (US)
14.20-14.40 Oncogene induced replication stress Z. Lygerou (GR)
14.40-15.00 Stress-induced senescence and role in tumor growth D. Kletsas (GR)
15.00-15.10 Discussion
Chairs: P. Makrythanasis (GR), A. Voutsina (GR)
15.10-15.30 Chromosomal aberrations and manifestations of genomic instability S. Gagos (GR)
15.30-15.50 Genomic instability as driver of tumor evolution G. Nasioulas (GR)
15.50-16.10 Telomeric instability S. Gagos (GR)
16.10-16.20 Discussion
Coffee Break
Chairs: A. Klinakis (GR), P. Constantoulakis (GR)
16.40-17.00 Molecular basis of HR Deficiency J. V. Forment (UK)
17.00-17.20 Synthetic lethality and PARP inhibitor technology, parylation Th. Rampias (GR)
17.20-17.40 Next generation of PARP inhibitors S. Linardopoulos (UK)
17.40-17.50 Discussion
Chairs: A. Giatromanolaki (GR), C.N. Baxevanis (GR)
17.50-18.10 Tumor microenvironment and immunogenicity I. Pateras (GR)
18.10-18.30 The heterogeneous landscape of metastatic tumor microenvironment D. Papachristou (GR)
18.30-18.50 Heterogeneity in tumor specific immune responses S. Fortis (GR)
18.50-19.00 Discussion
Chairs: I. Pateras (GR), G. Nasioulas (GR)
09.00-09.20 The NGS as a diagnostic tool for precision medicine E. Papadopoulou (GR)
09.20-09.40 HRD scoring platforms (technologies) P. Constantoulakis (GR)
09.40-10.00 Emerging HRD biomarkers and functional assays Α.Klinakis (GR)
10.00-10.10 Discussion
Chairs: A. Kotsakis (GR), V. Georgoulias (GR)
10.10-10.30 Targeting HRD in breast cancer A. Constantinidou (CY)
10.30-10.50 Targeting HRD in ovarian cancer I. Syrios (GR)
10.50-11.10 Targeting HRD in prostate cancer and pancreatic cancer Z. Zafiriou (GR)
11.10-11.30 Targeting HRD in the agnostic treatment setting M. Rovithi (GR)
11.30-11.40 Discussion
Coffee Break
Chairs: Α. Klinakis (GR), Ch. Emmanouilidis (GR)
12.00-12.20 HRD prevelance in other tumor types G. Christopoulou (GR)
12.20-12.40 Combination of PARP inhibition with immunotherapy R. Zakopoulou (GR)
12.40-13.00 Combination of PARP inhibitors with other treatments O. Fiste (GR)
13.00-13.20 Mechanisms of resistance to PARP inhibitors Th. Rampias (GR)
13.20-13.30 Discussion
Concluding Remarks